New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine

Title:

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine

Creator:

Davenport, A. P., Kuc, R. E., Maguire, J. J., and Southan, C.

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:8d193e04-ee75-4fac-9dda-c94e4cd6127f
uuid:8d193e04-ee75-4fac-9dda-c94e4cd6127f
issn:0862-8408

Subject:

fyziologie člověka, human physiology, Allosteric modulators, Biased signaling, G-protein coupled receptors, Endothelin-1, Monoclonal antibodies, Pepducins, Single nucleotide polymorphisms, 14, and 612

Type:

model:article and TEXT

Format:

print, bez média, and svazek

Description:

During the last thirty years since the discovery of endothelin-1, the therapeutic strategy that has evolved in the clinic, mainly in the treatment of pulmonary arterial hypertension, is to block the action of the peptide either at the ETA subtype or both receptors using orally active small molecule antagonists. Recently, there has been a rapid expansion in research targeting ET receptors using chemical entities other than small molecules, particularly monoclonal antibody antagonists and selective peptide agonists and antagonists. While usually sacrificing oral bio-availability, these compounds have other therapeutic advantages with the potential to considerably expand drug targets in the endothelin pathway and extend treatment to other pathophysiological conditions. Where the small molecule approach has been retained, a novel strategy to combine two vasoconstrictor targets, the angiotensin AT1 receptor as well as the ETA receptor in the dual antagonist sparsentan has been developed. A second emerging strategy is to combine drugs that have two different targets, the ETA antagonist ambrisentan with the phosphodiesterase inhibitor tadalafil, to improve the treatment of pulmonary arterial hypertension. The solving of the crystal structure of the ETB receptor has the potential to identify allosteric binding sites for novel ligands. A further key advance is the experimental validation of a single nucleotide polymorphism that has genome wide significance in five vascular diseases and that significantly increases the amount of big endothelin-1 precursor in the plasma. This observation provides a rationale for testing this single nucleotide polymorphism to stratify patients for allocation to treatment with endothelin agents and highlights the potential to use personalized precision medicine in the endothelin field., A. P. Davenport, R. E. Kuc, C. Southan, J. J. Maguire., and Seznam literatury

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Source:

Physiological research | 2018 Volume:67 | Number:Suppl 1

Harvested from:

CDK

Metadata only:

false